Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

Publication | Open Access

DOI Full Paper Access

578

Citations

References

2017

Year

Marc S. Sabatine, Lawrence A. Leiter, Stephen D. Wiviott, Robert P. Giugliano, Prakash Deedwania, Gaetano Maria De Ferrari, Sabina A. Murphy, Julia Kuder, Ioanna Gouni‐Berthold, Basil S. Lewis,

The Lancet Diabetes & Endocrinology

Metabolic SyndromeHypertensionDiabetes ManagementCardiovascular DiseasePcsk9 Inhibitor EvolocumabDiabetesPharmacologyCardiovascular SafetyPharmacotherapyDiabetes MellitusMedicineAtherosclerosisNew-onset Diabetes